Breast cancer (Tokyo, Japan)最新文献

{"title":"Impact of sentinel lymph node biopsy versus axillary lymph node dissection on shoulder range of motion in early rehabilitation after breast cancer surgery.","authors":"Honami Hieda, Yasunori Umemoto, Aoi Aasaumi, Naoki Hashimoto, Makoto Yamagishi, Kai Ushio, Akimitsu Yamada, Takeshi Nakamura","doi":"10.1007/s12282-026-01827-6","DOIUrl":"10.1007/s12282-026-01827-6","url":null,"abstract":"<p><p>BACKGROUND: The impact of early rehabilitation on shoulder range of motion (ROM) limitation following sentinel lymph node biopsy (SLNB) in breast cancer surgery remains insufficiently understood. This study evaluated postoperative changes in shoulder ROM by surgical procedure among patients with breast cancer who underwent early rehabilitation. METHODS: This retrospective study included patients with breast cancer who underwent total mastectomy with SLNB (n = 149) or axillary lymph node dissection (ALND) (n = 55). Rehabilitation commenced on postoperative day 1. Shoulder ROM was assessed preoperatively, immediately postoperatively, and at the end of outpatient rehabilitation. RESULTS: Preoperative ROM did not differ between groups. Both groups showed significant postoperative declines (p < 0.05). After rehabilitation, flexion and abduction improved significantly in both groups (p < 0.05). In the SLNB group, median flexion increased from 122.5° to 140°, abduction from 112.5° to 155.3°, and horizontal abduction from 12.5° to 25°. In the ALND group, flexion improved from 120° to 150°, abduction from 115° to 155°, and horizontal abduction from 10° to 20°. Although the SLNB group required fewer outpatient rehabilitation days (mean 36.6 vs. 45.9), final shoulder ROM was comparable between groups, with no significant differences at the end of rehabilitation. CONCLUSIONS: SLNB was associated with less severe postoperative shoulder ROM limitation than ALND, indicating that early rehabilitation may allow a more rapid recovery of ROM in SLNB patients. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"593-600"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PIK3CA mutation in ER-negative and HER2-positive breast cancer with apocrine differentiation.","authors":"Fumi Nozaki, Yoko Nakanishi, Yukari Hirotani, Hiroko Kobayashi, Tomoyuki Tanino, Haruna Nishimaki-Watanabe, Sumie Ohni, Xiaoyan Tang, Shinobu Masuda","doi":"10.1007/s12282-026-01837-4","DOIUrl":"10.1007/s12282-026-01837-4","url":null,"abstract":"<p><strong>Background: </strong>Targeted therapies for PIK3CA-mutated breast cancer are currently limited to the hormone receptor (HR)-positive and HER2-negative subtype. Carcinoma with apocrine differentiation (apocrine ca.) is typically characterized as ER-negative and HER2-positive/negative. Consequently, patients with apocrine ca. are generally excluded from PIK3CA genotyping and targeted therapies, even when mutations are present. Here, we investigated the prevalence and functional significance of PIK3CA mutations in apocrine ca., particularly in ER-negative (HER2-subtypes and triple-negative) subtypes.</p><p><strong>Methods: </strong>We analyzed hotspot PIK3CA mutations in apocrine ca. and invasive breast carcinoma of no special type (IBC-NST) (20 and 70 samples, respectively). PIK3CA knockdown was performed to compare the proliferation of breast cancer cell lines representing two types of apocrine ca. with PIK3CA mutations (MDA-MB-453: ER-/HER2+/AR + and MFM223: ER-/HER2-/AR+) and one without PIK3CA mutations (HCC1428: ER+/HER2-/AR-).</p><p><strong>Results: </strong>PIK3CA mutations occurred in apocrine ca. (3/20, 15.0%) and IBC-NST (2/70, 2.9%) cases (P = 0.071). Within the ER-negative and HER2-positive subtypes, PIK3CA mutations were present in 25% of apocrine ca. (2/8) cases, whereas no mutations were observed in positive IBC-NST (0/18) (P = 0.086). siRNA-mediated PIK3CA knockdown reduced the proliferation of MDA-MB-453 (P < 0.01) and MFM223 (P = 0.01) cells, whereas no effect was observed in HCC1428 cells (P = 0.674), relative to the non-targeting siRNA control.</p><p><strong>Conclusions: </strong>PIK3CA mutations are present in ER-negative and HER2-positive apocrine ca., and these mutations drive PIK3CA-dependent proliferation in vitro. These results suggest that patients with apocrine ca. may benefit from PIK3CA mutation testing and subsequent targeted therapy.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"625-633"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147274271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with central venous port implantation during breast cancer perioperative chemotherapy: a Japanese database study.","authors":"Mari Abe, Kojiro Morita, Takaaki Konishi, Katsuhiko Nara, Yuya Kimura, Kiyohide Fushimi, Hideo Yasunaga, Gojiro Nakagami","doi":"10.1007/s12282-026-01850-7","DOIUrl":"10.1007/s12282-026-01850-7","url":null,"abstract":"<p><p>BACKGROUND: Vascular access guidelines in Western countries recommend the central venous (CV) administration of cytotoxic chemotherapy agents to reduce complications such as extravasation. However, in Japan, peripheral venous administration is common. This study aimed to clarify the current status of using CV ports in Japan and its associated patient and institutional factors in breast cancer cases. METHODS: This retrospective cohort study used the Diagnosis Procedure Combination data documented between 2013 and 2022 from 238 hospitals. Participants were patients with breast cancer who underwent mastectomy and perioperative chemotherapy. Data on patient demographics, anticancer drugs used, and hospital characteristics were collected from the inpatient and outpatient episodes. Factors associated with CV port implantation were examined using logistic regression analysis. RESULTS: Among 45,960 patients, 113 (0.25%) underwent CV port implantation, mostly postoperatively and at trunk sites. Factors negatively associated with CV port use included partial mastectomy (Odds ratio, 0.62 [95% confidence interval,0.41–0.92]) (vs. total mastectomy), use of only irritant drugs (0.43[0.21–0.90]) (vs. vesicants), and treatment at medium-volume hospitals (0.34 [0.16–0.73]) (vs. low-volume hospitals), whereas use of both vesicant and irritant drugs or nonvesicant drugs, and high volume hospital did not show statistical significance. CONCLUSION: CV ports were used in only 0.25% of breast cancer surgery cases, suggesting highly selective utilization. Their implantation may be influenced not only by clinical factors but also by institutional characteristics and practice patterns, highlighting the need for the context-specific use of CV ports. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"736-743"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147629742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early outcomes of accelerated partial breast irradiation and dosimetric comparison of volumetric modulated arc therapy and three-dimensional conformal radiotherapy.","authors":"Tomomi Aoshika, Nobue Uchida, Fumihiro Tomita, Ryohei Yamauchi, Reiko Kondo, Ayako Kurose, Junko Takei, Atsushi Yoshida, Satoshi Ishikura","doi":"10.1007/s12282-026-01844-5","DOIUrl":"10.1007/s12282-026-01844-5","url":null,"abstract":"<p><p>BACKGROUND: Guidelines for partial breast irradiation as postoperative radiotherapy following breast-conserving therapy for breast cancer have been published; consequently, the National Comprehensive Cancer Network guidelines now designate accelerated partial breast irradiation (APBI) as a standard treatment option for these patients. APBI was introduced at our institution in July 2024. Here, we report the early clinical outcomes of the use of APBI and present a dosimetric comparison of volumetric modulated arc therapy (VMAT) and three-dimensional conformal radiotherapy (3D-CRT) in delivering APBI. METHODS: We performed a retrospective review of the charts of patients who underwent breast-conserving surgery followed by radiotherapy between July 2024 and May 2025. APBI was performed according to the ASTRO guidelines; specifically, 30 Gy was administered in 5 fractions every other day. Among patients receiving APBI, dosimetric parameters were compared between 3D-CRT and VMAT. Acute adverse events occurring within 28 days of treatment initiation were evaluated using the Common Terminology Criteria for Adverse Events, Version 5.0. RESULTS: Among the 268 patients, 109 were deemed suitable for APBI. Of these, 27 (25%) chose to undergo whole-breast irradiation, while 82 (75%) chose APBI. The median age in the APBI group was 56 years (range, 43–78). The pathologic tumor size was 2 cm or smaller in 63 patients and greater than 2 cm in 19 patients. Dosimetric parameter analysis revealed the superiority of VMAT over 3D-CRT in terms of target coverage and normal tissue sparing. Acute adverse events included grade 1 dermatitis in 65 (79%) patients and grade 1 breast pain in 4 (5%) patients; no grade 2 or worse events were reported. CONCLUSIONS: APBI with VMAT was completed without inducing severe acute toxicity in all the patients in this real-world setting. Long-term follow-up is needed to evaluate oncological outcomes and late toxicity. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"675-682"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147470794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B).","authors":"Hitomi Sakai, Rika Kusumoto-Matsuo, Mari Hosonaga, Kazuki Nozawa, Manabu Futamura, Yuko Tanabe, Toru Mukohara, Kazuhiro Shiraishi, Tatsuya Toyama, Hiroyuki Yasojima, Noriyuki Watanabe, Hideki Sakai, Tsutomu Iwasa, Nobumichi Takeuchi, Hiroshi Tada, Kazuko Sakai, Natsuko Chiba, Toshimi Takano, Junji Tsurutani","doi":"10.1007/s12282-026-01855-2","DOIUrl":"10.1007/s12282-026-01855-2","url":null,"abstract":"<p><p>BACKGROUND: A key resistance mechanism to PARP inhibitors is the development of BRCA1/2 reversion mutations that restore the protein function. METHODS: Patients with metastatic breast cancer and germline BRCA1/2 mutations were recruited from 14 institutions and treated with olaparib. Targeted next-generation sequencing was performed on circulating tumor DNA (ctDNA) extracted from blood collected at base line and progression on olaparib (Guardant360). The primary objective was to evaluate the frequency of BRCA1/2 reversion mutations in this group. RESULTS: From November 2021 to October 2023, 60 patients were enrolled. The median age was 50.5 years (32–85). Of these, 12 (20.0%) had germline BRCA1 mutation and 48 (80.0%) had germline BRCA2 mutation. The median number of prior chemotherapies was 2 (0–7). Two patients had received platinum. Among patients with tumor progression on olaparib who had available ctDNA results, BRCA1/2 reversion mutations were identified in 25.0% (2/8; 95% CI 3.2–65.1%) with germline BRCA1 mutation and 23.5% (8/34, 95% CI 10.7–41.2%) with germline BRCA2 mutation. In one patient, BRCA2 reversion mutations were found in ctDNA seven months before radiological confirmation of progression on olaparib and again after progression. Among the ten cases with BRCA1/2 reversion mutations, all but one case involved secondary indels on primary indel sites. Reversion mutations were not observed in the C-terminal regions of BRCA1/2. CONCLUSION: BRCA1/2 reversion mutations were detected in ctDNA as a mechanism of resistance to olaparib. Certain genomic regions and mutation types appeared to be particularly prone to reversion mutations. CLINICAL TRIAL REGISTRATION: UMIN000046007. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"790-797"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147648758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Niraparib in breast cancer: evidence-based perspective on translational progress.","authors":"Kushant Chauhan, Puja Kumari, Deepali Devi, Sneha Thakur, Sangeeta Thakur, Khushboo Bisht, Madhu Bala","doi":"10.1007/s12282-026-01856-1","DOIUrl":"10.1007/s12282-026-01856-1","url":null,"abstract":"<p><p>Breast cancer is the most prevalent malignancy in women throughout the world, with a high level of heterogeneity concerning the subtypes, posing challenges to long-term treatment success. Among the emerging therapeutic strategies, poly (ADP-ribose) polymerase (PARP) inhibitors have shown promise in targeting tumors with defects in homologous recombination repair, particularly those harbouring BRCA1/2 mutations. Niraparib, a highly potent selective PARP1/2 inhibitor administered orally, has demonstrated a high anti-tumor response in ovarian cancer and is currently undergoing clinical trials in breast cancer treatment. Though niraparib possesses structural and functional similarities to other approved agents such as olaparib and talazoparib, it is not yet approved for breast cancer. This serves as a research gap that requires critical consideration of its therapeutic positioning. This review offers an in-depth examination of pharmacological profile, mechanism of action, resistance mechanism, and the benefits of niraparib in BRCA-mutated homologous recombination deficient breast cancer. We also summarise findings from major clinical trials that assess niraparib as monotherapy and in combination with chemotherapy, immune checkpoint inhibitors, and radiotherapy. Furthermore, this review critically evaluates the safety profile, pharmacokinetics, and ongoing clinical studies. Besides these, this article highlights the translational horizons and a new combination strategy that can possibly expand the use of niraparib to a wider patient group. By bridging mechanistic science and clinical applications, this review highlights the potential of niraparib to unlock synthetic lethality and shape the future landscape of precision oncology in breast cancer.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"569-581"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147629699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial.","authors":"Yosuke Aoyama, Kosuke Kashiwabara, Yuichiro Kikawa, Naruto Taira, Hirofumi Mukai, Masato Takahashi","doi":"10.1007/s12282-026-01852-5","DOIUrl":"10.1007/s12282-026-01852-5","url":null,"abstract":"<p><p>BACKGROUND: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and breast cancer–specific quality-of-life questionnaire (QLQ-BR23) are widely used in clinical trials, but information on minimal important differences (MIDs) remain limited. METHODS: Data were obtained from the RESQ trial, a phase 3 study conducted in Japan. A total of 302 patients with HER2-negative metastatic breast cancer were randomized to receive eribulin or S-1. QLQ-C30 and QLQ-BR23 were administered every six weeks until week 24 and every nine weeks until week 42. The trial’s preplanned secondary analysis aimed to estimate group-level MIDs for both questionnaires. Subjective significance questionnaire and performance status (PS) served as anchors to estimate MIDs. RESULTS: Of the 302 patients, 270 were included in this analysis. The median age was 61 years. At baseline, 73.0% had a PS of 0, and 27.0% had a PS of 1 or 2. Within-group MIDs were estimated for 11 domains of the QLQ-C30 and 5 domains of the QLQ-BR23, ranging from 6 to 14 points for improvement and − 5 to − 17 points for deterioration. Between-group MIDs were estimated for 7 domains of the QLQ-C30, ranging from 4 to 7 points for improvement and − 4 to − 9 points for deterioration; none were estimated for the QLQ-BR23. CONCLUSIONS: This study provides the first MID estimates for the QLQ-BR23 and expands MID for the QLQ-C30 in patients with metastatic breast cancer. These findings offer benchmarks for interpreting quality-of-life outcomes and support the clinical relevance of patient-reported measures.[ 250 / 250 ]. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"752-760"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147577567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring a specialized lactylation pattern to predict the prognosis and sensitivity of immunotherapy in breast cancer via machine learning.","authors":"Lin Li, Mingrui Wang, Xin Li, Jinhua Ding","doi":"10.1007/s12282-026-01829-4","DOIUrl":"10.1007/s12282-026-01829-4","url":null,"abstract":"<p><p>BACKGROUND: With the global incidence of breast cancer steadily increasing, there is a critical need to explore novel molecular mechanisms that drive tumor progression and affect therapeutic response. Lactylation, a recently discovered post-translational modification, has been implicated in various aspects of tumor biology; however, its specific role in breast cancer (BRCA) remains poorly understood. Understanding the association between lactylation and BRCA may offer new insights into prognosis and precision treatment strategies. This study proposes a new framework for understanding the interplay between lactylation and breast cancer progression, with potential implications for prognostic modeling and immunotherapy guidance. METHODS: We performed a comprehensive integrative analysis using multi-omics data from TCGA-BRCA and three independent GEO cohorts. Breast cancer patients were classified into three distinct clusters based on the expression of lactylation-related genes, each exhibiting unique clinical and molecular profiles. To construct a robust prognostic model, 79 machine learning algorithms were evaluated, and the random survival forest (RSF) method was selected as the optimal approach. PGK1 was identified as the most critical predictive gene in the model. RESULTS: The RSF-based risk score demonstrated strong prognostic power and was significantly associated with immune cell infiltration and response to immunotherapy in BRCA patients. Functional validation experiments further confirmed that PGK1 knockdown (shPGK1) markedly suppressed breast cancer cell proliferation and migration in vitro. CONCLUSIONS: We developed a novel lactylation-related prognostic model that effectively predicts immunotherapy outcomes in breast cancer and highlights the central role of PGK1 in modulating tumor behavior and immune response. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"469-484"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-carbohydrate diet score and risk of breast cancer: findings from a prospective cohort study.","authors":"Yen Thi-Hai Pham, Renwei Wang, Jian-Min Yuan, Hung N Luu","doi":"10.1007/s12282-026-01826-7","DOIUrl":"10.1007/s12282-026-01826-7","url":null,"abstract":"<p><p>BACKGROUND: A low carbohydrate diet (LCD) reflects a dietary pattern characterized by reduced carbohydrate intake and higher consumption of protein and fat. Evidence on the role of LCD and risk of breast cancer is inconclusive. We, therefore, prospectively examined the association between LCD scores and breast cancer risk in the Singapore Chinese Health Study (SCHS). METHODS: We used data of 34,028 female participants in the SCHS, a prospective cohort study with subjects recruited in Singapore during 1993–1998 period. LCD scores were derived from the semi-quantitative food frequency questionnaire at baseline. Breast cancer cases were identified through record linkage with the Singapore cancer registry. Cox proportional hazard regression method was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer in relation to LCD scores. RESULTS: We identified 1,131 participants who developed breast cancer after 17.6 years of follow-up and 616,410 person-years. We found a modest inverse association between total LCD (HRper-SD increment = 0.94, 95% CI: 0.89–1.00; Ptrend = 0.05) and plant-based LCD scores with breast cancer risk (HRper-SD increment = 0.94, 95% CI: 0.89–1.00; Ptrend = 0.06). No association was found between animal-based LCD and risk of breast cancer (HRper-SD increment = 0.96, 95% CI: 0.90–1.02, Ptrend = 0.18). CONCLUSION: Our findings suggest that adherence to a LCD, particularly plant-based LCD may be protective against the development of breast cancer, highlighting the potential role of dietary modification in cancer prevention strategies. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"448-458"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146121834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial.","authors":"Riko Sato, Rena Kamohara, Tomohei Matsuo, Aya Sawa, Mai Okazaki, Sachie Hashimoto, Akiko Iguchi-Manaka, Hisato Hara, Kosuke Doki, Yuji Mukai, Masato Homma, Ryota Ishii, Kensuke Shimada, Hiroko Bando","doi":"10.1007/s12282-026-01828-5","DOIUrl":"10.1007/s12282-026-01828-5","url":null,"abstract":"<p><p>BACKGROUND: Although venlafaxine has shown efficacy for hot flashes in hormone receptor–positive breast cancer, evidence in Asian women (especially premenopausal) remains limited. Hot flashes reduce endocrine therapy adherence and severity may increase with ovarian suppression. We conducted a prospective, single-arm, open-label study to evaluate the efficacy and safety of venlafaxine in tamoxifen-treated patients with moderate-to-severe hot flashes. METHODS: Twenty patients received venlafaxine at 37.5 mg/day for 4 weeks, with optional escalation to 75 mg/day. Weekly hot flash scores, adverse events, and serum concentrations of tamoxifen, its metabolites, and venlafaxine (as well as CYP2D6 genotype associations) were assessed. Of the 20 patients, 17 were included in the primary efficacy analysis, 20 in the safety population for adverse events, and 18 in the pharmacokinetic analysis. RESULTS: At Week 4, hot flash scores declined by 49.8% from baseline (P < 0.001). Venlafaxine did not affect serum concentrations of tamoxifen or its metabolites. CYP2D6 intermediate metabolizers had higher venlafaxine concentrations than extensive metabolizers (P = 0.007), although symptom improvement occurred regardless of genotype. All adverse events were Grade 1–2. CONCLUSIONS: These findings demonstrate that venlafaxine safely and effectively alleviates hot flashes in hormone receptor-positive breast cancer patients undergoing tamoxifen-based endocrine therapy. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"459-468"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146129069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}